糖尿病治療及診斷：全球市場 是由出版商BCC Research在2010年06月所出版的。
這份英文市場調查報告書包含150 Pages 價格從美金4850起跳。
全球糖尿病治療及診斷市場預估於2010年成為300億美金，未來也將以CAGR 6.1％擴大，到2015年預測將達到512億美元。
本報告整理了糖尿病的概要與治療方法、各種治療及設備的概述、全球各地區市場的動向、代替胰島素投與的新式療法、主要企業簡介等內容，其綱要摘記如下。
第1章 前言
第2章 摘要
第3章 概述
- 糖尿病的基礎
- 成長市場
- 糖尿病的藥物治療
- 糖尿病用醫療儀器
- 成長市場
- 糖尿病業界
第4章 關於糖尿病
- 何謂糖尿病
- 診斷
- 現今治療方法
- 未來的治療方法
- 糖尿病監控
- 糖尿病的普及程度
- 糖尿病併發症
第5章 糖尿病治療
- 胰島素
- 注射器
- 吸入性胰島素
- 其他胰島素輸送方法
- 胰島素幫浦
第6章 口服降血糖藥物
第7章 診斷與監控
- 自我監測的角色
- 血糖監控設備：備品與產品
- 血糖檢測的新發展
- 其他檢測方法
- 軟體支援糖尿病監控
第8章 糖尿病市場
- 市場結構
- 北美
- 中南美洲
- 歐洲
- 西太平洋諸國
- 東南亞
- 各產品種類的市場分析
- 趨勢
第9章 糖尿病治療的新方法
- 胰島素的替代品
- 免疫療法
- 移植
- 細胞與幹細胞療法
- 基因治療
第10章 企業簡介
附錄
Abstract
- The global market for therapeutic and diagnostic products for diabetes is
valued at $38 billion in 2010. This market is expected to grow at a compound
annual growth rate (CAGR) of 6.1% to reach $51.2 billion in 2015.
- Insulin products, including administration devices, are worth an estimated
$16.4 billion in 2010. This sector is expected to reach $22 billion in 2015, a
6.1% compound annual growth rate (CAGR).
- Oral hypoglycemic drugs are expected to achieve the highest compound
annual growth rate (CAGR) of 8%, increasing from $10.3 billion in 2010 to
$15.1 billion in 2015.
INTRODUCTION
STUDY GOALS AND OBJECTIVES
The aim of this report is to provide detailed market, technology and industry
analyses to help readers quantify and qualify the market for prescription
generic drugs used in the treatment of diabetes and devices and instruments
used for diagnosis and monitoring of diabetes. Important trends are identified
and sales forecasts by product categories and major country markets are
provided through 2015; these are based on epidemiological data and
projections, plus information on R&D trends and differential market potential
on a country-by-country basis. Healthcare policies, demographics, and the
wider economic environment are also taken into account.
REASONS FOR DOING THE STUDY
It is widely recognized that the prevalence of the commonest type of diabetes
mellitus, Type 2, is now reaching epidemic proportions all over the world.
Cases of Type 1 DM are also on the increase, although to a less spectacular
degree. These trends are of great concern, not only to the individuals
concerned, but to governments and providers of healthcare, because the
economic consequences of diabetes are vast, as they involve not only the
direct burden of managing the disease but also the common and often
catastrophic complications including cardiovascular disease, peripheral
neuropathy and blindness.
Thus the prompt diagnosis and effective treatment of diabetes are essential,
not optional, priorities for governments and healthcare agencies. One
consequence is that the already large market for diabetes monitoring and
treatment will certainly grow in line with increasing incidence and with
improvements in diagnosis. Thus diabetes is of great commercial significance
to the suppliers of drugs used in treatment and devices needed for monitoring.
Among the information needs of companies in this field is accurate and
up-to-date assessment of the current extent of the diabetes epidemic, its
likely evolution over the next 5 years, and the impact of drugs and technical
developments now in the pipeline.
SCOPE OF REPORT
This report discusses the implications of the above-mentioned trends, in the
context of the current size and growth of the diabetes market, both in global
terms and analyzed by the most important national markets. Companies in the
relevant pharmaceutical and medical industries are discussed, with profiles of
the leaders and an update on M&A activity. Five-year global sales forecasts
are provided for main drug and device categories, and breakdowns are provided
for several national markets.
MARKET ANALYSIS AND FORECASTS
Market figures are based on revenues at the manufacturer level and are
projected at 2010-dollar value without attempting to predict the effect of
inflation/deflation.
Therapeutic categories quantified and forecast include insulins and oral
hypoglycemic agents, and devices including blood glucose monitors and
accessories.
METHODOLOGY
Primary research includes interviews with leading individuals in relevant
companies and medical associations; primary sources of published data include
epidemiological and economic studies, company annual reports, SEC filings, and
government publications. Secondary sources consist of literature searches,
industry journals, and other commercial publications. Data for market
estimates and forecasts are pooled from a range of sources, critically
assessed by BCC.
INTENDED AUDIENCE
This report is designed to satisfy the information needs of a wide variety of
individuals involved in the diabetes marketplace, including company senior
management executives seeking to base their strategic decisions on the best
available information on market forces and trends. However, it is also aimed
at managers and executives in marketing, research, planning, and sales
departments who need readable, comprehensive and up-to-date background on the
marketplace in which they are operating.
INFORMATION SOURCES
Sources of information included marketing strategists, industry executives,
government and professional agencies, and surveys of physicians. Company
annual reports and SEC filings, journal articles, and data from healthcare
institutions were also mined, as well as publications of relevant associations
such as the International Diabetes Federation and the American and British
Diabetic Associations.
Table of Contents
Chapter- 1: INTRODUCTION -- Complimentary 4
- STUDY GOALS AND OBJECTIVES 1
- REASONS FOR DOING THE STUDY 1
- SCOPE OF REPORT 2
- MARKET ANALYSES AND FORECASTS 2
- METHODOLOGY 2
- INTENDED AUDIENCE 2
- INFORMATION SOURCES 3
- ANALYST CREDENTIALS 3
- RELATED REPORTS 3
- BCC ONLINE SERVICES 4
- DISCLAIMER 4
Chapter-2: SUMMARY 2
- THE DIABETES MARKET 5
- LEADING COMPANIES 5
- SUMMARY TABLE DIABETES MARKET BREAKDOWN BY PRODUCT GROUPS, THROUGH 2015 ($
BILLIONS) 6
- SUMMARY FIGURE DIABETES MARKET EVOLUTION BY PRODUCT GROUP, 2010 AND 2015
($ BILLIONS) 6
Chapter-3: OVERVIEW 6
- DIABETES BASICS 7
- A GROWING MARKET 7
- DRUG TREATMENT OF DIABETES 8
- INSULIN 8
- ORAL ANTIDIABETIC DRUGS 8
- THE PHARMACEUTICAL DIABETES MARKET 8
- INSULIN ADMINISTRATION DEVICES 9
- MEDICAL DEVICES FOR DIABETES 9
- TABLE 1 TOTAL DIABETES MARKET ($) 10
- REGIONAL SEGMENTATION 10
- TABLE 2 ADULT DIABETES MARKET, BY REGION (MILLIONS/%) 11
- MARKET GROWTH 11
- THE DIABETES INDUSTRY 11
- PHARMACEUTICAL COMPANIES 12
- MEDICAL DEVICE COMPANIES 12
Chapter-4: ABOUT DIABETES 22
- WHAT IS DIABETES? 13
- BLOOD SUGAR REGULATION 13
- INSULIN 14
- TYPE 1 DIABETES 14
- TYPE 2 DIABETES 15
- GESTATIONAL DIABETES 16
- OBESITY-RELATED TYPE 2 DIABETES IN CHILDREN 16
- MATURE-ONSET DIABETES OF THE YOUNG (MODY) 17
- OTHER DIABETIC STATES 17
- DIAGNOSIS 17
- GLUCOSE TESTS 18
- OFFICIAL CRITERIA 18
- DIFFERENTIAL DIAGNOSIS 18
- Type 1 Diabetes 18
- Type 2 Diabetes 19
- CURRENT TREATMENT 19
- TYPE 1 DIABETES 19
- TABLE 3 MAIN BRANDS AND TYPES OF INSULIN 20
- TYPE 2 DIABETES 21
- Sulphonylureas 21
- Biguanides 22
- Alpha-glucosidase Inhibitors 22
- Glitazones (Thiazolidinediones) 22
- Prandial Glucose Regulators 22
- Incretin Mimetics 23
- DPP-4 Inhibitors 23
- TABLE 4 ORAL DIABETES TREATMENTS 23
- DIET 24
- FUTURE TREATMENT APPROACHES 24
- MONITORING DIABETES 25
- BLOOD SUGAR CONTROL 25
- THE DIABETES CONTROL AND COMPLICATIONS TRIAL 25
- The Diabetes Control and ... (Continued) 26
- GLYCATED HAEMOGLOBIN (HBA1C) 27
- FRUCTOSAMINE 28
- PREVALENCE OF DIABETES 28
- TABLE 5 PREVALENCE OF DIABETES BY REGION, 2010 AND 2030 (POPULATION AGED
20 TO 79) 29
- TYPE 1 30
- TYPE 2 30
- DIABETIC COMPLICATIONS 31
- RETINOPATHY 31
- NEUROPATHY 31
- NEPHROPATHY 32
- PREVALENCE BY REGION 33
- TABLE 6 PREVALENCE RANGE OF DIABETIC COMPLICATIONS BY REGION, 2006 33
- INCREASED MORTALITY RISK 33
- METABOLIC SYNDROME 34
Chapter-5: DIABETES THERAPIES 21
- INSULIN 35
- HISTORY 35
- Bovine and Porcine Insulin 36
- Humanized Insulin 37
- COMPANIES SUPPLYING INSULIN 37
- Eli Lilly 37
- Sanofi Aventis 38
- Novo Nordisk 38
- Some Other Suppliers 38
- Wockhardt Limited: India 38
- BioconB: India 39
- Shreya Life Sciences: India 39
- Diosynth: the Netherlands 39
- TABLE 7 MAJOR BRANDS OF INSULIN 39
- TABLE 7 (CONTINUED) 40
- INSULIN DELIVERY 40
- Syringes 40
- INSULIN SYRINGE MANUFACTURERS 41
- Becton Dickinson 41
- Owen Mumford 41
- Terumo 41
- B. Braun 41
- Pens 42
- TABLE 8 INSULIN PENS 42
- MANUFACTURERS OF INSULIN PENS 43
- Novo Nordisk 43
- Owen Mumford 43
- Other Makers 44
- INJECTORS 44
- INJECTOR MANUFACTURERS 45
- Activa Brand Products 45
- Antares Pharma 45
- Bioject 45
- MediCool, Inc 46
- Owen Mumford 46
- Palco Labs, Inc 46
- Rosch AG Medizintechnik 46
- INHALED INSULIN 46
- OTHER INSULIN DELIVERY APPROACHES 47
- Oral-Lyn 47
- Oramed 48
- Medingo Micro-pump Patch 48
- INSULIN PUMPS 48
- The Infusion Set 49
- Candidates for Pump Therapy 50
- COMPANIES SUPPLYING INSULIN PUMPS 51
- Animas Corporation 51
- Sooil Development Company 51
- Medtronic MiniMed 52
- Nipro Diabetes Systems 52
- Roche Disetronic 52
- Smiths Medical 53
- Insulet 53
- TABLE 9 INSULIN PUMPS 54
- Problems with Pumps or Users? 54
- Problems with Pumps or Users? (Continued) 55
Chapter-6: ORAL HYPOGLYCEMIC DRUGS 5
- SULFONYLUREAS 56
- TABLE 10 SULFONYLUREAS 56
- BIGUANIDES 56
- ALPHA-GLUCOSIDASE INHIBITOR 57
- GLITAZONES 57
- PRANDIAL GLUCOSE REGULATORS 57
- GLP-1 ANALOGS; ALSO KNOWN AS INCRETIN MIMETICS 58
- AMYLIN MIMETIC 58
- TABLE 11 ORAL HYPOGLYCEMICS 59
- NEW PRODUCTS NOW IN R&D 59
- Dutogliptin 59
- Taspoglutide 59
- Byetta LAR 60
- Lixisenatide 60
Chapter-7: DIAGNOSIS AND MONITORING 29
- THE ROLE OF SELF-MONITORING 61
- SMBG FREQUENCY 62
- BLOOD GLUCOSE MONITORING DEVICES: SUPPLIERS AND PRODUCTS 62
- LANCETS 63
- TABLE 12 INTERNATIONAL SUPPLIERS OF BLOOD LANCETS 63
- BLOOD SAMPLING DEVICES 63
- Bayer Diagnostics 64
- Becton Dickinson 64
- Cell Robotics 64
- LifeScan 64
- Roche Diagnostics 64
- BLOOD GLUCOSE MONITORS 65
- 77 Elektronica Kft 65
- Abbott Laboratories 65
- Acon Laboratories Inc. 66
- AgaMatrix Inc. 66
- Apex Biotechnology Corp. 67
- Arkray USA 67
- Aventir Biotech LLC 67
- Bayer Corporation 67
- Belbiosens 68
- Diagnostic Devices Inc. 68
- Eumed Biotechnology Co. Ltd. 68
- HMD Bio Medical 68
- GlucoPlus Inc 69
- Health & Life Co. 69
- HemoCue AB 69
- Home Diagnostics Inc 69
- Hypoguard 70
- i-SENS Inc. 70
- LifeScan Inc 70
- Medtronic MiniMed 70
- Menarini Diagnostics 71
- National Diagnostic Products 71
- Novabiomedical Corporation 71
- Roche 71
- TaiDoc Technology Corporation 72
- US Diagnostics Inc 72
- GLUCOSE METER ACCURACY 73
- NEW DEVELOPMENTS IN GLUCOSE TESTING 74
- CONTINUOUS GLUCOSE MONITORING (CGM) 74
- Continuous Glucose Monitoring ... (Continued) 75
- Reimbursement 76
- NON-INVASIVE MONITORING 76
- Non-invasive Monitoring (Continued) 77
- Non-invasive Monitoring (Continued) 78
- Non-invasive Monitoring (Continued) 79
- Non-invasive Monitoring (Continued) 80
- TABLE 13 SELECTED COMPANIES DEVELOPING NON-INVASIVE GLUCOSE MONITORING 81
- TABLE 13 (CONTINUED) 82
- ARTIFICIAL PANCREAS 82
- Roche 83
- Abbott 83
- Novo Nordisk/LifeScan 84
- OTHER TESTING APPROACHES 84
- HAEMOGLOBIN A1C 84
- Hemoglobin A1c Meters 84
- Hemoglobin A1c Kits 85
- SOFTWARE AIDS TO DIABETES MONITORING 86
- AIDA ON-LINE 86
- BAYER CARE: BLOOD SUGAR LOG 86
- BODY SIGMA 87
- DAILYRATING 87
- DIABETEASE 87
- DIABETES ASSISTANT 87
- DIABETES HOMECARE CENTER 88
- ECIVON 88
- HEALTHENGAGE DIABETES 88
- LIFECLINIC 88
- PLASMAGLUCOSE 89
- SYMCARE 89
Chapter-8: THE DIABETES MARKET 17
- MARKET COMPONENTS 90
- SIZE 90
- TABLE 14 GLOBAL DIABETES MARKET 2010 ($) 91
- GROWTH 91
- REGIONAL SEGMENTATION 92
- TABLE 15 REGIONAL SEGMENTATION OF DIABETES UNIVERSE, 2010 AND 2030
(MILLIONS/%) 92
- NATIONAL MARKETS 93
- NORTH AMERICA 93
- TABLE 16 U.S.: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 94
- TABLE 17 CANADA: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 94
- SOUTH AND CENTRAL AMERICA 94
- TABLE 18 ARGENTINA: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 95
- TABLE 19 BRAZIL: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 95
- TABLE 20 MEXICO: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 95
- EUROPE 96
- TABLE 21 BELGIUM: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 96
- TABLE 22 DENMARK: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 96
- TABLE 23 FRANCE: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 97
- TABLE 24 GERMANY: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 97
- TABLE 25 ITALY: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 97
- TABLE 26 NETHERLANDS: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 98
- TABLE 27 NORWAY: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 98
- TABLE 28 PORTUGAL: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 98
- TABLE 29 RUSSIA: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 99
- TABLE 30 SPAIN: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 99
- TABLE 31 SWEDEN: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 99
- TABLE 32 UNITED KINGDOM: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 100
- TABLE 33 EUROPEAN UNION: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 100
- WESTERN PACIFIC 100
- TABLE 34 AUSTRALIA: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 101
- TABLE 35 CHINA: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 101
- TABLE 36 JAPAN: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 101
- TABLE 37 SOUTH KOREA: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 102
- TABLE 38 TAIWAN: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 102
- SOUTH-EAST ASIA 102
- TABLE 39 INDIA: DIABETES MARKET, THROUGH 2015 ($ MILLIONS) 103
- MARKET ANALYSIS BY PRODUCT CATEGORY 103
- MONITORING PRODUCTS 103
- Major Suppliers 103
- TABLE 40 LEADING COMPANIES OF GLUCOSE MONITORING PRODUCTS, 2009 ($
MILLIONS/%) 103
- INSULINS AND INSULIN DELIVERY DEVICES 104
- Major Suppliers 104
- TABLE 41 GLOBAL SALES OF LEADING INSULIN PRODUCTS, 2009 ($ MILLIONS) 104
- INSULIN PUMPS 104
- TABLE 42 GLOBAL INSULIN PUMP MARKET, BY REGION, THROUGH 2015 ($ MILLIONS)
105
- OTHER ANTIDIABETIC DRUGS 105
- Major suppliers 105
- TABLE 43 SALES OF OTHER ANTIDIABETIC PRODUCTS, 2009 ($ MILLIONS) 106
- TRENDS 106
Chapter-9: NEW APPROACHES TO THE MANAGEMENT OF DIABETES 6
- ALTERNATIVES TO INSULIN 107
- IMMUNOTHERAPY 108
- TRANSPLANTATION 109
- CELL AND STEM CELL THERAPIES 110
- GENE THERAPY 111
- GENE THERAPY APPROACHES FOR EXPRESSING INSULIN 111
- GENE THERAPY APPROACHES FOR IMMUNOMODULATION 111
- GENE THERAPY APPROACHES FOR CELL-BASED THERAPIES 112
Chapter-10: COMPANY PROFILES 31
- LEADING COMPANIES 113
- ABBOTT LABORATORIES 113
- Overview 113
- Diabetes Products 113
- ABBOTT DIABETES CARE, INC. 114
- BAYER 115
- Overview 115
- Diabetes Products 116
- BECTON DICKINSON 116
- Overview 116
- Diabetes Products 117
- Insulin Injection Devices 117
- BRISTOL-MYERS SQUIBB 117
- Overview 117
- Problems with Generics 118
- Diabetes Products 118
- ELI LILLY AND COMPANY 118
- Overview 118
- Diabetes Products 119
- Pipeline 119
- GLAXO SMITHKLINE 119
- Overview 119
- Diabetes Products 120
- Pipeline 120
- TABLE 44 DIABETES PRODUCTS IN GSK PIPELINE 120
- JOHNSON & JOHNSON 120
- Overview 121
- Diabetes Products 121
- MEDTRONIC 122
- Overview 122
- Diabetes Products 122
- Pipeline 123
- MERCK KGAA 124
- Overview 124
- Diabetes Product 124
- NOVARTIS INTERNATIONAL AG 125
- Overview 125
- Diabetes Products 125
- Research 126
- NOVO NORDISK A/S 126
- Overview 126
- Diabetes Products 127
- Pharmaceuticals 127
- Injection devices 127
- Pipeline 128
- ROCHE 128
- Overview 128
- Diabetes Products 129
- Blood Glucose Monitoring Systems 129
- Diabetes Data Management 130
- Insulin Pump Systems 130
- Lancet Devices 131
- Other 131
- Pipeline 131
- SANOFI-AVENTIS 132
- Overview 132
- Diabetes Products 132
- TAKEDA 133
- Overview 133
- Pipeline 134
- TABLE 45 DIABETES PRODUCTS IN DEVELOPMENT BY TAKEDA 135
- OTHER COMPANIES 135
- 77 ELEKTRONIKA CO., LTD. 135
- AGAMATRIX, INC. 135
- ANIMAS CORPORATION 136
- DEBIOTECH S.A. 137
- INLIGHT SOLUTIONS, INC. 137
- LIFESCAN, INC. 138
- A. MENARINI DIAGNOSTICS S.R.L. 139
- NIPRO CORPORATION 139
- Nipro Corporation (Continued) 140
- OWEN MUMFORD LTD 141
- PALCO LABS, INC. 142
- TERUMO CORP. 142
- Terumo Corp. (Continued) 143
APPENDIX 7 $340
- APPENDIX 144
- TABLE 46 GLOSSARY 144
- TABLE 46 (CONTINUED) 145
- TABLE 46 (CONTINUED) 146
- TABLE 46 (CONTINUED) 147
- TABLE 46 (CONTINUED) 148
- TABLE 46 (CONTINUED) 149
- TABLE 46 (CONTINUED) 150
|
